Xavier Pi-Sunyer

Dr. Xavier Pi-Sunyer


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2006 in JAMA
Verified
Journal Article
Closed access
PDF file
XPXavier Pi-Sunyer
Xavier Pi-Sunyer
LALouis J. Aronne
Louis J. Aronne
HHHassan M. Heshmati
Hassan M. Heshmati
JDJeanne Devin
Jeanne Devin
JRJulio Rosenstock
Julio Rosenstock
FGfor the RIO-North America Study Group
for the RIO-North America Study Group
Research from JAMA — Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients — RIO-North America — A Randomized Controlled Trial — ContextRimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese.ObjectiveTo compare the efficacy and safety of rimonabant with placebo each in conjunction with diet and exercise for sustained changes in weight and cardiometabolic risk factors over 2 years.Design, Setting, and ParticipantsRandomized, double-blind, placebo-controlled trial of 3045 obese (body mass index ≥30) or overweight (body mass index >27 and treated or untreated hypertension or dyslipidemia) adult patients at 64 US and 8 Canadian clinical research centers from August 2001 to April 2004.InterventionAfter a 4-week single-blind placebo plus diet (600 kcal/d deficit) run-in period, patients were randomized to receive placebo, 5 mg/d of rimonabant, or 20 mg/d of rimonabant for 1 year. Rimonabant-treated patients were rerandomized to receive placebo or continued to receive the same rimonabant dose while the placebo group continued to receive placebo during year 2.Main Outcome MeasuresBody weight change over year 1 and prevention of weight regain during year 2. Additional efficacy measures included changes in waist circumference, plasma lipid levels, and other cardiometabolic risk factors.ResultsAt year 1, the completion rate was 309 (51%) patients in the placebo group, 620 (51%) patients in the 5 mg of rimonabant group, and 673 (55%) patients in the 20 mg of rimonabant group. Compared with the placebo group, the 20 mg of rimonabant group produced greater mean (SEM) reductions in weight (−6.3 [0.2] kg vs −1.6 [0.2] kg; P<.001), waist circumference (−6.1 [0.2] cm vs −2.5 [0.3] cm; P<.001), and level of triglycerides (percentage change, −5.3 [1.2] vs 7.9 [2.0]; P<.001) and a greater increase in level of high-density lipoprotein cholesterol (percentage change, 12.6 [0.5] vs 5.4 [0.7]; P<.001). Patients who were switched from the 20 mg of rimonabant group to the placebo group during year 2 experienced weight regain while those who continued to receive 20 mg of rimonabant maintained their weight loss and favorable changes in cardiometabolic risk factors. Use of different imputation methods to account for the high rate of dropouts in all 3 groups yielded similar results. Rimonabant was generally well tolerated; the most common drug-related adverse event was nausea (11.2% for the 20 mg of rimonabant group vs 5.8% for the placebo group).ConclusionsIn this multicenter trial, treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors. However, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study.Clinical Trials RegistrationClinicalTrials.gov Identifier: NCT00029861

1 December 2002 in Obesity Research
Verified
Journal Article
Closed access
PDF file
XPXavier Pi-Sunyer
Xavier Pi-Sunyer

1 April 2007 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
XPXavier Pi-Sunyer
Xavier Pi-Sunyer
ASAnja Schweizer
Anja Schweizer
DMDavid Mills
David Mills
SDSylvie Dejager
Sylvie Dejager

1 July 2002 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
XPXavier Pi-Sunyer
Xavier Pi-Sunyer
It has been suggested that foods with a high glycemic index are detrimental to health and that healthy people should be told to avoid these foods. This paper takes the position that not enough valid scientific data are available to launch a public health campaign to disseminate such a recommendation. This paper explores the glycemic index and its validity and discusses the effect of postprandial glucose and insulin responses on food intake, obesity, type 1 diabetes, and cardiovascular disease. Presented herein are the reasons why it is premature to recommend that the general population avoid foods with a high glycemic index.

1 November 1999 in Medicine & Science in Sports & Exercise
Verified
Journal Article
Closed access
XPXavier Pi-Sunyer
Xavier Pi-Sunyer
PI-SUNYER, F. X. Comorbidities of overweight and obesity; current evidence and research issues. Med. Sci. Sports Exerc., Vol. 31, No. 11, Suppl., pp. S602–S608, 1999. The evidence with regard to the relationship of obesity with medical comorbidities was assessed and priority research issues identified. The existing literature in English was surveyed. The evidence is overwhelming on the association of obesity to a number of medical conditions. These include: insulin resistance, glucose intolerance, diabetes mellitus, hypertension, dyslipidemia, sleep apnea, arthritis, hyperuricemia, gall bladder disease, and certain types of cancer. The independent association of obesity seems also clearly established for coronary artery disease, heart failure, cardiac arrhythmia, stroke, and menstrual irregularities. The relationship between central (or upper body) obesity and the above conditions is positive for most of them but with a lesser number of studies. Most of the fat distribution studies have been done using anthropometric measurements rather than the more accurate magnetic resonance imaging or computer tomographic scans. Priority research issues include the following: more definitive data on the relation of central fat to comorbidities; the proportional importance of subcutaneous versus visceral fat in producing comorbidities; the relationship between obesity and psychiatric disease; the genetics of the relationship between obesity and each of the comorbidities; the independent contribution of diet and of sedentariness to the development of each of the comorbidities; the impact of gender, race, intensity, and duration on these associations. The evidence for the relationship of obesity to a number of comorbidities is strong, though the strength of the relationship varies with the condition. Much more research is necessary on causation and on what other factors may play an interactive role.

28 September 2014 in Current Nutrition Reports
Verified
Journal Article
Closed access
PDF file
XPXavier Pi-Sunyer
Xavier Pi-Sunyer